Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aktis Oncology, Inc.NASDAQ: AKTS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development of $20.04M in Q1 FY2026
Q1 FY2026 research & development was $20.04M. Over 3 fiscal years it compounded at +67.7% a year.
Context
- Research & development amounted to 1038.2% of revenue in FY2025, down 1715.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 67.45M USD
- Year-over-year change
- +64.7%
- 3-year CAGR
- +67.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.45M | +64.7% |
| FY2024 | 2024-12-31 | 40.95M | +58.0% |
| FY2023 | 2023-12-31 | 25.92M | +81.2% |
| FY2022 | 2022-12-31 | 14.3M | — |
Research & Development vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's FY2025 research & development of $67.45M is the lowest of the 6 companies compared; the peer median is $230.13M.
- Its year-over-year change of +64.7% is the highest of 6, against a peer median of +17.2%.
- Research & development amounts to 1038.2% of revenue for AKTS, versus a peer median of 86.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $259.11M | +17.2% | +34.4% | 67.2% | |
| LTM Sep 2026 | $236.54M | +35.6% | +95.7% | — | |
| LTM Mar 2026 | $230.13M | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $94.92M | +19.3% | +28.8% | — | |
| FY2025 | $67.45M | +64.7% | +67.7% | 1038.2% | |
| Peer median (excluding AKTS) | $230.13M | +17.2% | +34.4% | 86.2% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.49M | 6.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 1.49M | 6.5M |
| Gross Margin | — | — | 100.0% | 100.0% |
| Research & Development | 14.3M | 25.92M | 40.95M | 67.45M |
| Selling, General & Admin | 5.11M | 7.68M | 11.31M | 12.6M |
| Operating Expenses | 19.76M | 34.79M | 53.54M | 81.18M |
| Depreciation & Amortization | 445K | 1.2M | 1.58M | 2.33M |
| EBITDA | (17.48M) | (27.45M) | (42.41M) | (61.4M) |
| EBITDA Margin | — | — | -2851.7% | -945.1% |
| Operating Income | (19.76M) | (34.79M) | (52.05M) | (74.68M) |
| Operating Margin | — | — | -3500.3% | -1149.5% |
| Interest Income | 1.65M | 5.38M | 8.1M | 11.01M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.84M | 6.15M | 8.07M | 10.95M |
| Income Before Tax | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Pre-Tax Margin | — | — | -2957.6% | -980.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Net Margin | — | — | -2957.6% | -980.9% |
| EPS (Basic) | (0.51) | (0.82) | (1.26) | (1.19) |
| EPS (Diluted) | (0.51) | (0.82) | (1.26) | (1.19) |
| Weighted Avg Shares | 34.86M | 34.86M | 34.86M | 52.52M |
| Weighted Avg Shares (Diluted) | 34.86M | 34.86M | 34.86M | 52.52M |
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.